19:44 , May 9, 2019 |  BC Extra  |  Clinical News

May 9 Clinical Quick Takes: Polyphor, BMS, Cel-Sci, University of Pittsburgh, Merck, Scholar Rock, Promethera

Polyphor halts Phase III enrollment of pneumonia therapy  Polyphor Ltd. (SIX:POLN) said late Thursday it will suspend enrollment in the Phase III PRISM-MDR and PRISM-UDR trials of pneumonia antibiotic murepavadin (POL7080) after observing a 56%...
00:06 , Apr 6, 2019 |  BioCentury  |  Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
18:53 , Oct 27, 2017 |  BC Week In Review  |  Clinical News

FDA lifts hold on Cel-Sci's Ph III trial of Multikine in SCCHN

Cel-Sci Corp. (NYSE-M:CVM) said FDA lifted a clinical hold on the Phase III IT-MATTERS trial of Multikine leukocyte interleukin injection to treat squamous cell carcinoma of the head and neck (SCCHN). The open-label, international trial...
19:38 , Jun 23, 2017 |  BC Week In Review  |  Clinical News

Cel-Sci submits response regarding FDA's hold on Phase III trial of Multikine

Cel-Sci Corp. (NYSE-M:CVM) said it responded to a May communication from FDA regarding a partial clinical hold the agency placed in September 2016 on a Phase III trial of Multikine leukocyte interleukin injection to treat...
16:07 , May 4, 2017 |  BC Week In Review  |  Financial News

Cel-Sci raises $1.5M in direct public offering

On May 1, cancer and infectious disease company Cel-Sci Corp. (NYSE-M:CVM) raised $1.5 million through the sale of 13.2 million shares at $0.115 in a registered direct offering with an institutional investor. In a concurrent...
19:58 , Mar 10, 2017 |  BC Week In Review  |  Financial News

Cel-Sci completes direct public offering

Cancer and infectious disease company Cel-Sci Corp. (NYSE-M:CVM) raised $1.5 million through the sale of 15 million shares at $0.10 in a registered direct offering to institutional investors on March 9. Investors also received five-and-one-half-year...
02:18 , Feb 24, 2017 |  BC Week In Review  |  Financial News

Cel-Sci completes private placement

On Feb. 17, cancer and infectious disease company Cel-Sci Corp. (NYSE-M:CVM) raised $1 million through the sale of 10 million shares at $0.10 in a registered direct offering to institutional investors. Investors also received five-year...
21:51 , Dec 2, 2016 |  BC Week In Review  |  Financial News

Cel-Sci completes private placement of common stock and warrants

Cel-Sci raised $4.3 million through the sale of 34 million shares at $0.125. Investors also received five-year warrants to purchase up to 17 million shares at $0.20; six-month warrants to purchase up to 34 million...
07:00 , Oct 3, 2016 |  BC Week In Review  |  Clinical News

Multikine leukocyte interleukin injection: Phase III hold

Cel-Sci said it received verbal notice from FDA that the agency placed a clinical hold on an open-label, international Phase III trial comparing Multikine plus standard of care (SOC) vs. SOC alone. Cel-Sci said patients...